文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

氟哌利多在美国急诊科的有效性与安全性

Effectiveness and safety of droperidol in a United States emergency department.
PubMed 文献 · Am J Emerg Med · 2019-11-25
一句话结论大型观察性队列显示急诊使用氟哌利多作为镇痛、止吐和/或镇静时未见死亡病例,作者认为其有效且安全。

该观察性队列研究纳入2012年1月1日至2018年4月19日某学术急诊科所有氟哌利多给药记录,共6,881次就诊、5,784例患者,其中6,353次就诊授权使用病历用于研究,儿童占5.4%、≥65岁老年人占8.2%。氟哌利多用于头痛(57.0%)、疼痛(21.8%)、镇静(8.7%)和止吐(12.5%)。主要终点24小时内死亡为零,无致命性心律失常,静坐不能发生率2.9%;头痛患者需补救镇痛5.2%、需补救阿片类1.1%,非头痛疼痛患者需补救镇痛7.4%、需补救阿片类5.4%。作者认为氟哌利多作为镇痛、止吐和/或镇静时有效且安全。

要点

  • 6,353次氟哌利多给药就诊中,24小时内无死亡病例记录,无致命性心律失常。
  • 氟哌利多最常用于头痛(57.0%)和疼痛(21.8%),其次为止吐(12.5%)和镇静(8.7%)。
  • 头痛患者中5.2%需补救镇痛、1.1%需补救阿片类;非头痛疼痛患者中7.4%需补救镇痛、5.4%需补救阿片类。
  • 静坐不能发生率为2.9%。
  • 儿童占5.4%、≥65岁老年人占8.2%的给药,作者认为氟哌利多作为镇痛、止吐和/或镇静时有效且安全。

适用人群与场景

  • 2012年1月1日至2018年4月19日某学术急诊科所有接受氟哌利多给药的就诊患者,共6,881次就诊、5,784例患者,其中6,353次就诊授权使用病历用于研究。
  • 给药人群包括儿童(占5.4%)和≥65岁老年人(占8.2%)。

研究设计与关键结果

  • 观察性队列研究,纳入2012年1月1日至2018年4月19日某学术急诊科所有氟哌利多给药记录,共6,881次就诊、5,784例患者,其中6,353次就诊授权使用病历用于研究。
  • 氟哌利多使用指征:头痛3,622次(57.0%)、疼痛1,387次(21.8%)、镇静550次(8.7%)、止吐794次(12.5%)。
  • 主要终点24小时内死亡:无因氟哌利多给药导致的死亡记录。
  • 次要终点补救镇痛:头痛患者中5.2%(N=188)需补救镇痛,1.1%(N=38)需补救阿片类;非头痛疼痛患者中7.4%(N=102)需补救镇痛,5.4%(N=75)需补救阿片类。
  • 无致命性心律失常;静坐不能发生率2.9%。

证据类型、等级与局限

  • 证据类型:观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,氟哌利多作为镇痛、止吐和/或镇静用于急诊科患者时有效且安全。
  • 该队列中24小时内无死亡、无致命性心律失常,静坐不能发生率2.9%。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Droperidol is a dopamine receptor antagonist that functions as an analgesic, sedative, and antiemetic. In 2001, the U.S. Food and Drug Administration required a black box warning in response to case reports of QT prolongation and potential fatal arrhythmias. The aim of this study was to evaluate the effectiveness and safety of droperidol in patients presenting to a United States Emergency Department (ED).

METHODS: Observational cohort study of all droperidol administrations from 1/1/2012 through 4/19/2018 at an academic ED. The primary endpoint was mortality within 24 h of droperidol administration. Secondary endpoint included use of rescue analgesics.

RESULTS: A total of 6,881 visits by 5,784 patients received droperidol of whom 6,353 visits authorized use of their records for research, including 5.4% administrations in children and 8.2% in older adults (≥65). Droperidol was used as an analgesic for pain (N = 1,387, 21.8%) and headache (N = 3,622, 57.0%), as a sedative (N = 550, 8.7%), and as an antiemetic (N = 794, 12.5%). No deaths secondary to droperidol administration were recorded within 24 h. Need for rescue analgesia occurred in 5.2% of patients with headache (N = 188) and 7.4% of patients with pain (N = 102); 1.1% of patients with headache received rescue opioids (N = 38) after droperidol, as did 5.4% of patients with pain other than headache (N = 75). No patients had fatal arrhythmias. Akathisia occurred in 2.9%.

CONCLUSION: No fatalities were seen among this large cohort of patients who received droperidol in the ED. Our findings suggest droperidol's effectiveness and safety when used as an analgesic, antiemetic and/or sedative.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Gaw CM, Cabrera D, Bellolio F, et al. Effectiveness and safety of droperidol in a United States emergency department. Am J Emerg Med. 2019. PMID: 31831345. doi:10.1016/j.ajem.2019.09.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。